Circular Genomics
Albuquerque, US · Founded 2021 · Delaware corporation · 18 employees on LinkedIn · 5 known investors
Find your way into Circular Genomics
674 people in our graph share verified history with the Circular Genomics team — schools, employers, funds. One of them is your warm intro.
Rustyunlockedknows Alexander Hafez · together at Techstars (overlapped)
×11knows the team · via Techstars
Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests. The company serves researchers, clinicians, and biopharma partners with diagnostic tools for conditions like Alzheimer's and Parkinson's.
Founders & leadership
Circular Genomics was founded in 2021 by Alexander Hafez.
AH
Alexander HafezinCo-Founder / Chief Executive Officer2020–2024Alexander Hafez is an executive officer and director at Circular Genomics, which develops a circular RNA biomarker platform for blood-based early detection of neurological diseases such as Alzheimer's and Parkinson's. His background spans project management and financial management, including fundraising, investments, and venture capital.
NM
Nikolaos MelliosNamed on SEC filing
Investors · 5
Cottonwood Technology FundDenver · $1M – $25M
Mountain Group CapitalNashville
Tramway Venture Partnersreported · 2 sourcesNew Mexico · $30M
Also in the syndicate · 2
Mountain Group PartnersleadUNM Rainforest Innovations
Funding
SEC filings, press & company announcements$27.6M disclosed across 4 of 5 rounds · 2021–2025
- $15MSeries ADec 2025 · 3 sourcesSource ↗
▶$8.3MraisedJan 2024 · 9 investors · BiotechnologyRule 506(b)
▶$8.3MraisedJan 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fortunado RoccaDirector
- David BlivinDirector
- Paul SargeantExecutive Officer, Director
- Waneta TuttleDirector
- Nikolaos MelliosDirector
- Joseph Cook IIIDirector
- Offering amount
- $15M
- Amount sold
- $8.3M
- Minimum investment
- $100K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3.1MraisedMar 2023 · 7 investors · BiotechnologyRule 506(b)
▶$3.1MraisedMar 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen McKernanExecutive Officer
- Cathy PettiDirector
- Blivin DavidDirector
- Fortunado RoccaDirector
- Alexander HafezExecutive Officer, Director, Promoter
- Nikolaos MelliosExecutive Officer, Director, Promoter
- Paul SargeantExecutive Officer, Director
- Joseph Cook IIIDirector
- Waneta TuttleDirector
- Offering amount
- $3.2M
- Amount sold
- $3.1M
- Proceeds to insiders
- $850K
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.2MraisedAug 2021 · 7 investors · BiotechnologyRule 506(b)
▶$1.2MraisedAug 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander HafezExecutive Officer, Director, Promoter
- Nikolaos MelliosDirector, Promoter
- Offering amount
- $2M
- Amount sold
- $1.2M
- Proceeds to insiders
- $300K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Oup7 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Polaris Genomics6 shared keywordsPolaris Genomics is a Veteran-owned biotech startup mapping molecular biomarkers to develop objective, biologically-based diagnostics and novel therapeutics for mental health and neuropsychiatric conditions such as PTSD. It combines genomics and AI to advance precision mental health care.
IDbyDNA5 shared keywordsScalable, high throughput DNA sequencing platforms.
Bionity5 shared keywordsBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.
Companies competing with Circular Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Circular Genomics do?
- Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests. The company serves researchers, clinicians, and biopharma partners with diagnostic tools for conditions like Alzheimer's and Parkinson's.
- Who founded Circular Genomics?
- Circular Genomics was founded by Alexander Hafez in 2021.
- Who are Circular Genomics's investors?
- Circular Genomics's investors include Cottonwood Technology Fund, Mountain Group Capital, Tramway Venture Partners.
- How much funding has Circular Genomics raised?
- Circular Genomics has disclosed $27.6M raised across 4 of its 5 known rounds.
- Where is Circular Genomics headquartered?
- Circular Genomics is headquartered in Albuquerque, US.